Alzheimer’s drug slows disease progression in trials

Pharmaceutical companies said their drug lecanemab reduced cognitive and functional decline by 27% compared to a placebo over 18 months in a phase 3 study of 1,800 patients with early-stage Alzheimer’s. The drug was also associated with higher incidences of brain swelling and small bleeds, although the company said they were rarely symptomatic. “Today’s announcement … Read more

A cancer-fighting version of herpes shows promise in early human trials

An illustration of a herpes simplex virus. Illustration: Shutterstock (Shutterstock) Scientists may be able to turn a longtime bacterial enemy into a cancer-fighting ally, new research suggests this week. In preliminary data from a phase I trial, a genetically modified version of the herpes virus has shown promise in treating difficult-to-eradicate tumors, with one patient … Read more

Viral Vectors and Plasmid DNA Manufacturing Market Size is

New York, United States, Sept. 22, 2022 (GLOBE NEWSWIRE) — Vectors are instruments that are used to carry genetic material into cells, and viral vectors are one such tool. Viruses have developed specific mechanisms that allow them to transfer their genomes into the cells that they infect. This represents a significant evolutionary step for viruses. … Read more

Ukrainian President Zelenskyy speaks at the UN General Assembly

Ukrainian President Volodymyr Zelenskyy visits the Kharkiv region for the first time since Russia launched attacks against his country on February 24 in Kharkiv region, Ukraine on May 29, 2022. (Photo taken by the Presidency of Ukraine/Handout/Anadolu Agency via Getty Images) The Ukrainian Presidency | Anadolu Agency | Getty Images [The stream is slated to … Read more

Crispr Gene-Editing Drugs Show Promise in Preliminary Study

Intellia Therapeutics Inc. reported encouraging early study results for their Crispr gene-editing treatments, the latest sign that the breakthrough technology could result in commercially available drugs in the coming years. Intellia said Friday that one of its treatments, codenamed NTLA-2002, significantly reduced the level of a protein that causes periodic swelling attacks in six patients … Read more

New cancer drug beats chemotherapy in study

New data from the first of a new type of cancer drug suggest its benefits and limitations, while leaving room for other candidates seeking to enter the lucrative market. Amgen Inc.’s Lung cancer pill Lumakras beat standard chemotherapy in a late-stage study and helped patients survive without their tumors getting worse, although it failed to … Read more

Moderna Inc. stock rises Thursday, better than the market

Shares in Moderna Inc. mRNA, +4.73% rose 4.73% to $141.28 on Thursday in what turned out to be a thoroughly stellar trading session for the stock market, with the NASDAQ Composite Index COMP, +0.60% up 0.60% to 11,862.13 and the Dow Jones Industrial Average DJIA, +0.61% rising 0.61% to 31,774.52. This was the stock’s second … Read more

Illumina’s deal to buy a cancer test developer has been blocked by the EU

BRUSSELS – The European Union blocked Illumina Inc.’s ILMN 2.52% acquisition of cancer test developer Grail Inc., putting a $7.1 billion merger in jeopardy just days after a U.S. administrative law judge allowed it to go ahead. The fate of the acquisition has emerged as an early test case for regulators in the US and … Read more

Illumina Wins Case Against FTC Over Grail Acquisition

Illumina said the judge rejected the FTC’s position that the deal would harm competition in the market for early multicancer tests. “As we’ve said from the start, this transaction is pro-competitive, will drive innovation, lower healthcare costs and save lives,” said Charles Dadswell, general counsel for Illumina. The decision, which FTC staff can appeal, suggests … Read more

CDC panel recommends new omicron Covid boosters with shots expected to begin next week

Justin Sullivan | Getty Images The Centers for Disease Control and Prevention’s Independent Committee on Vaccines recommended reformulated booster shots that target the latest omicron subvariants. The panel voted 13 to 1 Thursday in favor of the shots after reviewing the available safety and effectiveness data in a nearly seven-hour meeting. CDC Director, Dr. Rochelle … Read more